Vyne stops en­rolling ear­ly-stage pso­ri­a­sis study fol­low­ing clin­i­cal hold lift, ear­ly da­ta

Vyne Ther­a­peu­tics made sev­er­al an­nounce­ments Wednes­day re­gard­ing its ear­ly-stage in­flam­ma­to­ry dis­ease as­set, cul­mi­nat­ing in the de­ci­sion to stop en­rolling pa­tients in a Phase 1b pso­ri­a­sis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER